Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Quality of life in early breast cancer patients after adjuvant accelerated partial-breast irradiation (APBI) in randomized trial

P. Burkon, I. Selingerova, M. Vrzal, M. Holanek, O. Coufal, K. Polachova, V. Andraskova, SR. Jhawar, P. Slampa, T. Kazda, M. Slavik

. 2025 ; 15 (1) : 1387. [pub] 20250109

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010300

Grantová podpora
MMCI, 00209805 Ministerstvo Zdravotnictví Ceské Republiky
LX22NPO5102 Ministerstvo Školství, Mládeže a Tělovýchovy
LM2023049 Ministerstvo Školství, Mládeže a Tělovýchovy

Accelerated partial breast irradiation (APBI) represents a valid option for adjuvant therapy of selected early breast cancer (BC). This single-institution prospective randomized study compares the health-related quality of life (HRQoL) between women treated with the highly conformal-external beam APBI technique and those with the more commonly used moderately hypofractionated whole breast irradiation (hypo-WBI). Eligible patients were women over 50 years with early BC (G1/2 DCIS ≤ 25 mm or G1/2 invasive non-lobular luminal-like HER2 negative carcinoma ≤ 20 mm) after breast-conserving surgery with negative margins. APBI arm consisted of 30 Gy in 5 consecutive daily fractions and WBI arm of 40 Gy in 15 fractions plus 10 Gy in 5 fractions boost to the tumor bed. Patients were requested to complete the official Czech translation of the EORTC QoL questionnaires, including QLQ-C30 and QLQ-BR45, before radiation (baseline), at the end of radiation (M0) and 1 (M1), 3 (M3), 6 (M6), 12 (M12), and 24 (M24) months after radiation. Linear regression models were used to analyze differences in HRQoL between the arms. The 85 enrolled patients exhibited no differences in HRQoL scores between the two arms at baseline. Patients in the APBI arm reported more favorable global health status at M6 (p = 0.055). Other functional scales showed a decrease in the WBI arm at M0 (p = 0.027 for physical functioning). During radiation, symptoms scores increased. Significant between-group differences were observed for the pain (p = 0.002), systemic therapy side effects (p = 0.004), and breast symptoms (p < 0.001) scales at M0, with higher scores in the WBI arm. During follow-up, scores on symptoms scales returned to at least the baseline values. Early BC patients treated with APBI showed non-inferior short-term and late HRQoL outcomes compared to hypo-WBI. In addition to previous findings regarding toxicity, promising pain and breast symptoms results, suggest that APBI should be strongly considered as a treatment option for selected low-risk patients.Trial registration NCT06007118, August 23, 2023 (retrospectively registered).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010300
003      
CZ-PrNML
005      
20250429135329.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-025-85342-2 $2 doi
035    __
$a (PubMed)39779797
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Burkon, Petr $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Quality of life in early breast cancer patients after adjuvant accelerated partial-breast irradiation (APBI) in randomized trial / $c P. Burkon, I. Selingerova, M. Vrzal, M. Holanek, O. Coufal, K. Polachova, V. Andraskova, SR. Jhawar, P. Slampa, T. Kazda, M. Slavik
520    9_
$a Accelerated partial breast irradiation (APBI) represents a valid option for adjuvant therapy of selected early breast cancer (BC). This single-institution prospective randomized study compares the health-related quality of life (HRQoL) between women treated with the highly conformal-external beam APBI technique and those with the more commonly used moderately hypofractionated whole breast irradiation (hypo-WBI). Eligible patients were women over 50 years with early BC (G1/2 DCIS ≤ 25 mm or G1/2 invasive non-lobular luminal-like HER2 negative carcinoma ≤ 20 mm) after breast-conserving surgery with negative margins. APBI arm consisted of 30 Gy in 5 consecutive daily fractions and WBI arm of 40 Gy in 15 fractions plus 10 Gy in 5 fractions boost to the tumor bed. Patients were requested to complete the official Czech translation of the EORTC QoL questionnaires, including QLQ-C30 and QLQ-BR45, before radiation (baseline), at the end of radiation (M0) and 1 (M1), 3 (M3), 6 (M6), 12 (M12), and 24 (M24) months after radiation. Linear regression models were used to analyze differences in HRQoL between the arms. The 85 enrolled patients exhibited no differences in HRQoL scores between the two arms at baseline. Patients in the APBI arm reported more favorable global health status at M6 (p = 0.055). Other functional scales showed a decrease in the WBI arm at M0 (p = 0.027 for physical functioning). During radiation, symptoms scores increased. Significant between-group differences were observed for the pain (p = 0.002), systemic therapy side effects (p = 0.004), and breast symptoms (p < 0.001) scales at M0, with higher scores in the WBI arm. During follow-up, scores on symptoms scales returned to at least the baseline values. Early BC patients treated with APBI showed non-inferior short-term and late HRQoL outcomes compared to hypo-WBI. In addition to previous findings regarding toxicity, promising pain and breast symptoms results, suggest that APBI should be strongly considered as a treatment option for selected low-risk patients.Trial registration NCT06007118, August 23, 2023 (retrospectively registered).
650    _2
$a lidé $7 D006801
650    12
$a kvalita života $7 D011788
650    12
$a nádory prsu $x radioterapie $x chirurgie $x psychologie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a adjuvantní radioterapie $x škodlivé účinky $x metody $7 D018714
650    _2
$a prospektivní studie $7 D011446
650    _2
$a segmentální mastektomie $7 D015412
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Selingerova, Iveta $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic. iveta.selingerova@mou.cz $u Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czech Republic. iveta.selingerova@mou.cz
700    1_
$a Vrzal, Miroslav $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic
700    1_
$a Holanek, Milos $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Coufal, Oldrich $u Department of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Polachova, Katerina $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Andraskova, Vera $u Clinical Nutrition Unit, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Jhawar, Sachin R $u Radiation Oncology Department, Arthur James Cancer Center, The Ohio State University, Columbus, USA
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic
700    1_
$a Slavik, Marek $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53, Czech Republic. marek.slavik@mou.cz $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. marek.slavik@mou.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 15, č. 1 (2025), s. 1387
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39779797 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135324 $b ABA008
999    __
$a ok $b bmc $g 2311576 $s 1247381
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 15 $c 1 $d 1387 $e 20250109 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a MMCI, 00209805 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a LX22NPO5102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a LM2023049 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace